Barcelona Liver Bioservices (BLB) is pleased to announce a non-exclusive partnership with the global healthcare company Novo Nordisk aimed at characterizing the effects of novel chemical entities developed by Novo Nordisk for the treatment of chronic liver disease.

Barcelona Liver Bioservices in collaboration with Gilead Sciences, is excited to announce the results of an original study that showcases the potential of targeting the LPA pathway in the treatment of advanced chronic liver disease.